华纳药厂参股公司收到ZG-002片Ⅰ期临床研究报告

Core Viewpoint - Warner Pharmaceuticals (688799.SH) announced that its associate company, Shanghai Zhigen Pharmaceutical Technology Co., Ltd. (referred to as "Zhigen Pharmaceutical"), has completed Phase I clinical trials for its independently developed drug ZG-002 under the approval of the National Medical Products Administration [1] Group 1: Drug Development - ZG-002 is a novel drug with a new structure aimed at treating moderate to severe plaque psoriasis, classified as a Class 1 new drug [1] - The primary objective of the clinical trial was to evaluate the safety, tolerability, pharmacokinetic characteristics, and food effects of ZG-002 in healthy adult subjects [1] - The current dosing regimen of ZG-002 has shown good safety and tolerability, with clear pharmacokinetic characteristics [1] Group 2: Future Research - The clinical data obtained from this study supports the further exploration of additional clinical research in patient populations [1]